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Background
Somatic mutations in the Janus kinase 2 gene (JAK2) occur in many myeloprolifera-
tive neoplasms, but the molecular pathogenesis of myeloproliferative neoplasms 
with nonmutated JAK2 is obscure, and the diagnosis of these neoplasms remains a 
challenge.
Methods
We performed exome sequencing of samples obtained from 151 patients with myelo-
proliferative neoplasms. The mutation status of the gene encoding calreticulin 
(CALR) was assessed in an additional 1345 hematologic cancers, 1517 other cancers, 
and 550 controls. We established phylogenetic trees using hematopoietic colonies. 
We assessed calreticulin subcellular localization using immunofluorescence and 
flow cytometry.
Results
Exome sequencing identified 1498 mutations in 151 patients, with medians of 6.5, 
6.5, and 13.0 mutations per patient in samples of polycythemia vera, essential throm-
bocythemia, and myelofibrosis, respectively. Somatic CALR mutations were found in 
70 to 84% of samples of myeloproliferative neoplasms with nonmutated JAK2, in 
8% of myelodysplasia samples, in occasional samples of other myeloid cancers, and 
in none of the other cancers. A total of 148 CALR mutations were identified with 
19 distinct variants. Mutations were located in exon 9 and generated a +1 base-pair 
frameshift, which would result in a mutant protein with a novel C-terminal. Mutant 
calreticulin was observed in the endoplasmic reticulum without increased cell-surface 
or Golgi accumulation. Patients with myeloproliferative neoplasms carrying CALR mu-
tations presented with higher platelet counts and lower hemoglobin levels than pa-
tients with mutated JAK2. Mutation of CALR was detected in hematopoietic stem and 
progenitor cells. Clonal analyses showed CALR mutations in the earliest phylogenetic 
node, a finding consistent with its role as an initiating mutation in some patients.
Conclusions
Somatic mutations in the endoplasmic reticulum chaperone CALR were found in a 
majority of patients with myeloproliferative neoplasms with nonmutated JAK2. 
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The myeloproliferative neoplasms are chronic myeloid cancers that are char-acterized by the overproduction of mature 
blood cells, and that may evolve into acute my-
eloid leukemia.1,2 In addition to chronic myeloid 
leukemia with the BCR-ABL fusion gene, the three 
most common myeloproliferative neoplasms are 
essential thrombocythemia, polycythemia vera, 
and myelofibrosis.
Many patients with a BCR-ABL–negative myelo-
proliferative neoplasm carry a Janus kinase 2 
(JAK2) V617F mutation.3-6 The JAK2 V617F muta-
tion or JAK2 exon 12 mutations are found in 
most patients with polycythemia vera,7,8 whereas 
the JAK2 V617F mutation is found in only 50 to 
60% of patients with essential thrombocythemia 
or myelofibrosis.9,10 Tests for JAK2 mutations have 
greatly simplified the diagnosis of myeloprolif-
erative neoplasms and are now firmly embedded 
as front-line tests in national and international 
guidelines.11-14 However, distinguishing essen-
tial thrombocythemia with nonmutated JAK2 
from the much more common reactive thrombo-
cytosis remains a major diagnostic challenge.
Additional mutations have been identified in 
patients who have myeloproliferative neoplasms 
with or without JAK2 mutations. These mutations 
fall into two main classes: signaling mutations 
that activate the thrombopoietin receptor (MPL) 
or inactivate negative regulators such as LNK15,16 
and mutations in epigenetic regulators of DNA 
methylation (TET2, DNMT3A, and IDH1/2)17-20 or 
chromatin structure (EZH2 and ASXL1).21,22 How-
ever, these additional mutations affect only a 
small minority of patients, genomewide data are 
lacking, and the pathogenesis of myeloprolifera-
tive neoplasms without JAK2 or MPL mutations 
remains obscure.
We have used massively parallel sequencing 
to characterize the mutational landscape of 151 
patients with myeloproliferative neoplasms and 
have identified the gene encoding calreticulin 
(CALR) as a new cancer gene that is mutated in 
the majority of patients with myeloproliferative 
neoplasms and nonmutated JAK2.
Me thods
Study Samples
We obtained samples from patients with myelo-
proliferative neoplasms and other cancers and 
from healthy controls after obtaining written in-
formed consent. The study was approved by the 
ethics committee at each participating study cen-
ter. For exome sequencing, we obtained tumor 
samples from blood granulocytes and constitu-
tional samples from cultured T cells (in 34 pa-
tients), isolated T cells (in 42), or buccal swabs 
(in 75). (Additional details are provided in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org.) We classified all 
myeloproliferative neoplasms in accordance with 
the criteria of the British Committee for Standards 
in Haematology.11,12 The diagnoses of other hema-
tologic neoplasms were made in accordance with 
2008 World Health Organization categories.13
DNA Sequencing, Clonal Analysis,  
and Protein Expression
We performed exome sequencing of matched tu-
mor and constitutional samples of DNA using 
standard protocols and conducted bioinformatic 
analyses to identify somatically acquired muta-
tions, as described previously.23,24 We confirmed 
the presence of somatic sequence variants using 
custom target-capture methods and parallel se-
quencing combined with manual data curation. 
We used Sanger sequencing of CALR exon 9 com-
bined with analyses of exome or genome se-
quencing data to determine the mutation status 
of CALR in an additional 1345 hematologic can-
cers, in 1517 other cancer samples, and in 550 
control samples.
We cultured hematopoietic colonies, as de-
scribed previously,25 and genotyped them using 
Sanger sequencing for all mutations identified 
on exome sequencing for that patient. Expression 
constructs, cell lines, and other methods are 
described in the Supplementary Appendix.
Statistical Analysis
We calculated the significance of recurrently mu-
tated genes, taking into account mutation fre-
quency, gene size, and mutation and sequence 
context. P values were adjusted for a false discov-
ery rate and are expressed as a q value, with a 
value of less than 0.05 indicating statistical sig-
nificance. Clonal heterogeneity was inferred 
from exome-sequencing data on the basis of a 
Bayesian Dirichlet process.26 We evaluated the 
statistical significance of differences between 
subtypes of myeloproliferative neoplasms using 
standard methods, which are detailed in the Sup-
plementary Appendix. 
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R esult s
Mutational Landscape in the Patients
We analyzed the results of exome sequencing of 
DNA from granulocytes and constitutional DNA 
obtained from purified T cells or buccal cells in 
168 patients with myeloproliferative neoplasms. 
The identification of appropriate constitutional 
DNA samples is a challenge among patients with 
myeloproliferative neoplasms, since circulating 
T cells and buccal cells may be contaminated by 
neoplastic cells (Fig. S1 in the Supplementary Ap-
pendix). For patients with the JAK2 V617F muta-
tion, we measured the JAK2 V617F allele burden, 
using a quantitative polymerase-chain-reaction 
(PCR) assay to identify contaminated constitu-
tional DNA samples, with in vitro T-cell cultures 
being necessary in some instances. In cases in 
which constitutional DNA was limited, the use of 
a combination of unamplified and whole-genome 
amplified DNA improved exome coverage (Fig. S2 
in the Supplementary Appendix). We developed a 
bioinformatics workflow to enable the identifi-
cation of high-confidence somatic variants (Fig. 
S3 in the Supplementary Appendix), and comple-
mented this with orthogonal verification of mu-
tations by targeted resequencing and manual 
curation.
Of the 168 samples of myeloproliferative neo-
plasms that were sequenced, 151 samples (48 
samples of polycythemia vera, 62 of essential 
thrombocythemia, 39 of myelofibrosis, and 2 of 
unclassifiable myeloproliferative neoplasms) ful-
filled the bioinformatic criteria and were taken 
forward for analysis (Fig. S3 and Table S1 in the 
Supplementary Appendix). The average exome se-
quencing coverage was 141×.
We identified and validated 1498 somatic mu-
tations in 150 samples, with a range of 1 to 32 
mutations per sample (Fig. 1A, and Table S2 in 
the Supplementary Appendix); no mutations were 
identified in the sample obtained from Patient 
PD8641, who had essential thrombocythemia. A 
total of 99 of the mutations we identified were 
insertions or deletions (indels) and 1399 were 
substitutions; 1405 mutations were found in cod-
ing sequences (1130 nonsynonymous changes), 
22 in essential splice sites, 46 in introns within 
10 base-pairs of splice junctions, and 25 in un-
translated regions. The median number of muta-
tions per patient was 6.5 in patients with poly-
cythemia vera, 6.5 in those with essential 
thrombocythemia, and 13.0 in those with myelo-
fibrosis (P = 0.008 by one-way analysis of variance). 
The significantly higher number of mutations in 
patients with myelofibrosis was consistent with 
the concept that this disorder is a more advanced 
stage of disease than either essential thrombo-
cythemia or polycythemia vera (P<0.001 for the 
comparison of myelofibrosis with essential 
thrombocythemia and P = 0.008 for the com-
parison of myelofibrosis with polycythemia vera; 
pairwise t-test with Bonferroni correction for 
both comparisons). The mutational spectrum 
showed a predominance of C→T transitions (Fig. 
S4 in the Supplementary Appendix) and was 
similar to that observed in myelodysplasia and 
several epithelial cancers.23,27
We identified mutations in several genes that 
have previously been implicated in myeloprolif-
erative neoplasms or other myeloid cancers (Fig. 
1B and 1C). JAK2 V617F was the most prevalent 
mutation and was found in all 48 patients with 
polycythemia vera, 35 of 62 patients with essen-
tial thrombocythemia (56%), and 27 of 39 patients 
with myelofibrosis (69%). Mutations in epige-
netic regulators were as follows: TET2, 25 somatic 
variants in 22 patients; DNMT3A, 13 somatic vari-
ants in 12 patients; ASXL1, 13 somatic variants in 
12 patients; EZH2 somatic variants in 4 patients; 
and IDH1/2 somatic variants in 3 patients (Fig. 1B). 
Mutations in genes encoding components of the 
splicing machinery were found in 9 patients 
(U2AF1 in 4 patients, SF3B1 in 3 patients, and 
SRSF2 in 2 patients), and mutations in the gene 
encoding the thrombopoietin receptor (MPL) 
were identified in 7 patients, all of whom had 
essential thrombocythemia or myelofibrosis with 
unmutated JAK2. Mutations in genes that are 
reported to be mutated in myeloproliferative neo-
plasms at low frequencies were found in 4 pa-
tients (CBL, in 1 patient; NFE2, in 2 patients; and 
SH2B3/LNK, in 1 patient) (Fig. 1B). Missense so-
matic mutations in CHEK2, which have not been 
reported previously in myeloproliferative neo-
plasms, were found in 1 patient each with poly-
cythemia vera, essential thrombocythemia, and 
myelofibrosis (q = 0.008) (Table S3 in the Supple-
mentary Appendix). We also assessed pairwise 
associations between genes mutated in myelo-
proliferative neoplasms (Fig. S5 in the Supple-
mentary Appendix). Mutations in ASXL1 were 
found to be comutated with genes involved in 
RNA splicing (U2AF1 and SRSF2), and mutations 
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in SRSF2 were comutated with genes that en-
code epigenetic modifiers (TET2, IDH1, and ASXL1) 
— a profile strikingly similar to the associations 
seen in myelodysplasia.28
Recurrent Somatic CALR Mutations
A striking pattern of somatic mutations was ob-
served in CALR, a gene that had not previously 
been recognized as an oncogene mutated in any 
form of cancer. CALR mutations were identified 
in 26 patients (Fig. 1B and 1C). All the mutations 
were indels in exon 9 and had a remarkable as-
sociation with disease, since they were found in 
26 of 31 patients with essential thrombocythe-
mia or myelofibrosis and nonmutated JAK2 or 
MPL (84%; 95% confidence interval [CI], 66 to 
94) but in none of the 120 patients with JAK2 or 
MPL mutations (Fig. 2A, and Fig. S5 in the Sup-
plementary Appendix). There were two common 
variants: L367fs*46, which resulted from a 52-bp 
deletion flanked by 7 base pairs of identical se-
quence; and K385fs*47, which resulted from a 
5-bp insertion and represented an inverse dupli-
cation of the five nucleotides preceding the in-
sertion (Fig. 2B).
Exome sequencing revealed low coverage at 
CALR (median depth, 10 reads) (Fig. S6 in the 
Supplementary Appendix). We therefore also 
performed Sanger sequencing of exon 9, which 
detected CALR mutations in 10 to 15% of cells 
(Fig. S6 in the Supplementary Appendix). This 
confirmed the absence of CALR exon 9 muta-
tions in all 120 patients who had JAK2 or MPL 
mutations. Of 6 patients initially lacking a muta-
tion in CALR, JAK2, and MPL on exome sequenc-
ing, 1 patient was found to have low-level mu-
tated CALR on Sanger sequencing.
Among patients with essential thrombocythe-
mia, those with CALR mutations, as compared 
with those with JAK2 mutations, presented with 
significantly higher platelet counts (P<0.001 by 
the Wilcoxon rank-sum test) and lower hemoglo-
bin levels (P = 0.02 by Student’s t-test) (Table S4 
in the Supplementary Appendix). Patients with 
CALR mutations had a significantly higher inci-
dence of transformation from essential throm-
bocythemia to myelofibrosis than did those with 
JAK2 mutations (P = 0.03 by Fisher’s exact test) 
(Table S4 in the Supplementary Appendix). There 
were no significant between-group differences 
in rates of survival, although the number of 
deaths was small.
Exome sequencing showed that 146 of 151 
patients with myeloproliferative neoplasms (97%) 
had mutations in JAK2, MPL, or CALR in a mutu-
ally exclusive manner (q<0.01) (Fig. S5 in the 
Supplementary Appendix). The results of bone 
marrow histologic analyses were reviewed in 4 of 
the 5 patients lacking mutations in all three 
genes and were consistent with a myeloprolifera-
tive neoplasm. In addition, 4 of these patients 
(PD9420, PD8945, PD8635, and PD7441) had 
clonal somatic mutations, an indication that 
these patients had a clonal myeloid disorder 
(Table S2 in the Supplementary Appendix).
To further characterize CALR mutations in 
myeloid and other cancers, we performed Sanger 
sequencing of CALR exon 9 in 1397 samples (in-
cluding 52 control samples) and evaluated whole-
exome or whole-genome sequencing data for 502 
solid tumors, 498 control samples, and 1015 
cancer cell lines (Table 1). CALR mutations were 
present in 110 of 158 patients with myeloprolif-
erative neoplasms lacking JAK2 or MPL muta-
tions (70%; 95% CI, 62 to 77), including 80 of 
112 patients with essential thrombocythemia 
(71%), 18 of 32 patients with primary myelofi-
brosis (56%), and 12 of 14 patients with progres-
sion of essential thrombocythemia to myelofi-
brosis (86%). No CALR mutations were found in 
511 myeloproliferative neoplasms with JAK2 or 
MPL mutations. Secondary acute myeloid leuke-
mia developed in 2 patients with CALR mutations 
(1 each with essential thrombocythemia and 
myelofibrosis, both with the K385fs*47 variant), 
with persistence of the CALR mutations after 
Figure 1 (facing page). Mutational Profile of 151 
 Myeloproliferative Neoplasms.
Panel A shows the number and type of mutations iden-
tified on exome sequencing in each sample obtained 
from 151 patients with myeloproliferative neoplasms. 
These patients included 48 with polycythemia vera (PV), 
62 with essential thrombocythemia (ET), 39 with myelo-
fibrosis (MF), and 2 with unclassifiable myeloprolifera-
tive neoplasms (MPN-U). The type of mutation is indi-
cated in the key in each panel; the circles below the graphs 
indicate the patients’ mutational status: JAK2, MPL, or 
no JAK2 or MPL mutation. Also shown are the numbers 
of somatic mutations in recurrently mutated genes in 
this study as well as in genes previously reported to be 
mutated in myeloproliferative neoplasms, according to 
the type of mutation (Panel B) and subtype of myelo-
proliferative neoplasm (Panel C). In Panel B, the asterisks 
denote the significance of recurrently mutated genes 
(q<0.05). Indel denotes insertion or deletion mutation.
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Figure 2. CALR Mutations in Myeloproliferative Neoplasms.
Panel A shows the number of CALR mutations found in myeloproliferative neoplasms (polycythemia vera, PV; essential thrombocythe-
mia, ET; or myelofibrosis, MF) that have mutated JAK2, mutated MPL, or nonmutated JAK2 or MPL. Panel B shows the results of valida-
tion on polymerase-chain-reaction (PCR) assay and Sanger sequencing of the two most common CALR variants — deletion (L367fs*46) 
and insertion (K385fs*47) — in patients with myeloproliferative neoplasms. The patients are indicated by their patient-identification 
numbers above the results of gel electrophoresis of PCR products of patients’ granulocytes (Gran) and T cells. The sequencing traces 
show the heterozygous mutation of CALR. The shaded region on the left highlights a homologous DNA sequence flanking the common 
CALR deletion, and the green arrow on the right highlights the inverse tandem duplication of five bases in the common CALR insertion. 
Panel C shows the genomic location of CALR deletions. The numbers indicate the number of patients with each disease. Panel D shows 
the genomic location of CALR insertions (shown in red). aCML denotes atypical chronic myeloid leukemia, CMML chronic myelomono-
cytic leukemia, and MDS myelodysplastic syndromes.
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transformation. CALR mutations were identified 
in 10 of 120 patients with myelodysplastic syn-
dromes (8%; 95% CI, 4 to 15) (Table 1). One 
patient each with chronic myelomonocytic leu-
kemia and atypical chronic myeloid leukemia 
had CALR mutations. No mutations were found 
in control samples, lymphoid cancers, solid tu-
mors, or cell lines (Table 1, and Table S5 in the 
Supplementary Appendix).
Overall, CALR exon 9 mutations were identified 
in 148 patients (Table S6 in the Supplementary Ap-
pendix). All mutations were indels with 19 distinct 
variants: 14 deletions, 2 insertions, and 3 complex 
indels (Fig. 2C and 2D). In these 148 patients, vari-
ants L367fs*46 and K385fs*47 were the most com-
mon CALR mutations (in 67 patients [45%] and 
61 patients [41%], respectively). The remaining 
20 patients were found to have 17 unique vari-
ants. L367fs*46 was found more frequently in 
myelofibrosis than was K385fs*47 (P = 0.009 by 
chi-square test).
Mutant Protein with a Novel C-Terminal
Calreticulin is a highly conserved protein with 
multiple reported functions. Within the endo-
plasmic reticulum, the protein ensures appropri-
ate folding of newly synthesized glycoproteins 
and modulates calcium homeostasis.29,30 Outside 
the endoplasmic reticulum, calreticulin is also 
found in intracellular, cell-surface, and extracel-
lular compartments, where it has been implicated 
in diverse biologic processes, including prolifera-
tion, apoptosis, and immunogenic cell death.31-34 
Calreticulin has three main structural and func-
tional domains: an N-terminal lectin-binding do-
main that is interrupted by a proline-rich P domain 
and an unstructured C-terminal acidic domain that 
contains multiple calcium-binding sites.30,35
All the CALR indel mutations that were de-
tected are predicted to generate mutant proteins 
with a novel C-terminal (Fig. 3A). The extent of 
the C-terminal alterations vary, but all 19 dis-
tinct variants share a loss of a sequence of 27 
amino acids with a concomitant gain of a novel 
peptide consisting of 36 amino acids. These altera-
tions result in the loss of most of the C-terminal 
acidic domain and the KDEL signal. (The KDEL 
amino acid sequence [Lys-Asp-Glu-Leu] is pres-
ent on some resident endoplasmic reticulum 
proteins and enables retrieval of these proteins 
from the Golgi apparatus back to the endoplas-
mic reticulum.) This loss of function raises the 
possibility of compromised retention or retrieval 
in the endoplasmic reticulum. All CALR mutations 
shift the reading frame by one base pair, a pat-
tern of mutation that is very different from that 
observed in known tumor-suppressor genes such 
as TET2 and ASXL1 (Fig. 3B).36,37 Such genes are 
affected by nonsense mutations and indels, with 
the latter generating +1 and +2 base-pair frame-
shifts that frequently cause premature protein 
termination. The remarkably stereotypical pat-
tern of CALR mutations implies a strong selective 
pressure to generate the mutant C-terminal.
To confirm that CALR mutations result in a 
mutant protein product, CALR variant constructs 
(L367fs*46, deletion, and K385fs*47, insertion) 
were transiently expressed in human embryonic 
kidney (HEK) 293T cells. Immunoblotting con-
firmed the expression of mutant CALR proteins 
(Fig. 4A). Immunofluorescence studies of COS-7 
cells showed that mutant CALR did not accumulate 
in the Golgi apparatus (Fig. 4B) and colocalized 
with exogenously expressed nonmutant CALR 
(Fig. 4C). Similar studies comparing mutated 
and nonmutated CALR myeloid cells from two 
patients with CALR-mutated essential thrombo-
cythemia also showed no differences in the 
pattern of endogenous CALR (Fig. 4D).
The up-regulation of cell-surface CALR is re-
ported to mediate the phagocytosis of blasts38 in 
acute myeloid leukemia and might be a conse-
quence of altered cellular localization of CALR 
due to loss of KDEL. We measured cell-surface 
CALR in hematopoietic 32D cells expressing 
mutant CALR variants (L367fs*46 and K385fs*47) 
and found no differences from nonmutant CALR 
expression (Fig. S7 in the Supplementary Appen-
dix). Consistent with these results, there was no 
significant increase in cell-surface CALR in pe-
ripheral-blood leukocytes from five patients with 
mutated CALR (with estimated tumor burdens of 
40 to 100% in granulocytes from exome sequenc-
ing), as compared with normal controls (Fig. 4E). 
Our data do not exclude the possibility of partial 
loss of mutant CALR from the endoplasmic re-
ticulum through the secretory pathway.
CALR Mutations in the Hematopoietic-Stem-
Cell Compartment
CALR mutations were identified in patient-derived 
granulocyte–macrophage colonies and in ery-
throid colonies (Fig. S8 in the Supplementary Ap-
pendix), indicating that the mutations occur in a 
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Table 1. Frequency of CALR Mutations in Samples Obtained from Patients with Myeloproliferative Neoplasms or Other 
Disorders and from Controls.*
Tumor Type No. of Samples CALR Mutations
Occurrence Frequency
no./total no. % (95% CI)
Exome screening
Myeloproliferative neoplasms 151
Polycythemia vera 0/48 0
Essential thrombocythemia
With JAK2 or MPL mutation 0/40 0
Without JAK2 or MPL mutation 18/22 82 (59–94)
Myelofibrosis
Primary myelofibrosis
With JAK2 or MPL mutation 0/22 0
Without JAK2 or MPL mutation 4/5 80 (30–99)
After essential thrombocythemia
With JAK or MPL mutation 0/2 0
Without JAK or MPL mutation 4/4 100 (40–100)
After polycythemia vera 0/6 0
 Unclassifiable myeloproliferative neoplasm 0/2 0
Follow-up screening
Myeloproliferative neoplasm 669
Polycythemia vera 0/217 0
Essential thrombocythemia
With JAK2 or MPL mutation 0/138 0
Without JAK2 or MPL mutation 80/112 71 (62–79)
Myelofibrosis
Primary myelofibrosis
With JAK2 or MPL mutation 0/97 0
Without JAK2 or MPL mutation 18/32 56 (38–73)
After essential thrombocythemia
With JAK2 or MPL mutation 0/18 0
Without JAK2 or MPL mutation 12/14 86 (56–98)
After polycythemia vera 0/41 0
Other myeloid disorder 389
Myelodysplastic syndromes 10/120 8 (4–15)
Refractory anemia 5/53 9 (4–21)
RARS 3/27 11 (3–30)
Refractory anemia with excess blasts 2/17 12 (2–38)
Refractory anemia (5q-) 0/4 0
RARS and thrombocytosis 0/6 0
RCMD 0/10 0
RCMD and ringed sideroblasts 0/3 0
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multipotent progenitor capable of generating 
both myeloid and erythroid progeny. Consistent 
with these results, genotyping studies of three 
patients showed that CALR mutations were pres-
ent in flow-sorted, highly enriched hematopoietic 
stem cells (HSC; lin−CD34+CD38−CD45RA−CD90+), 
common myeloid progenitors (lin−CD34+CD38+ 
CD90−CD10−FLK2+CD45RA−), granulocyte–macro-
phage progenitors (lin−CD34+CD38+CD90−CD10−
FLK2+CD45RA+), and megakaryocyte–erythroid 
progenitors (lin−CD34+CD38+CD90−CD10−FLK2−
CD45RA−) (Fig. S8 in the Supplementary Appen-
dix). These data are consistent with CALR muta-
tions arising in the HSC compartment.
To ascertain whether mutation in CALR is an 
early event, we used exome-sequencing data to 
infer the fraction of cells bearing mutations and 
predict clonal relationships using a Bayesian 
Dirichlet process (Fig. S9 in the Supplementary 
Appendix). The results suggest that CALR muta-
Table 1. (Continued.)
Tumor Type No. of Samples CALR Mutations
Occurrence Frequency
no./total no. % (95% CI)
Chronic myelomonocytic leukemia 1/33 3 (0–18)
Atypical chronic myeloid leukemia 1/29 3 (0–20)
Chronic myeloid leukemia 0/28 0
Acute myeloid leukemia 0/48 0
Eosinophilic disorder 0/2 0
Systemic mastocytosis 0/114 0
Idiopathic erythrocytosis 0/5 0
Transient abnormal myelopoiesis 0/10 0
Lymphoid cancer 287
Acute lymphoblastic leukemia 0/62 0
Multiple myeloma 0/73 0
Chronic lymphocytic leukemia 0/77 0
Diffuse large B-cell lymphoma 0/25 0
MALT lymphoma 0/26 0
Splenic marginal-zone lymphoma 0/24 0
Solid tumors 502
Breast 0/190 0
Lung 0/28 0
Prostate 0/30 0
Colorectal 0/110 0
Skin 0/25 0
Bone 0/80 0
Renal 0/26 0
Meningioma 0/13 0
Cell lines 1015 0/1015 0
Control samples 550 0/550 0
* Mutations in the gene encoding calreticulin (CALR) were identified from whole-exome sequencing and validated by 
 targeted resequencing in the exome screening cohort. For the follow-up screening, CALR mutations were identified on 
Sanger sequencing of CALR exon 9 for myeloproliferative neoplasms, other myeloid disorders, lymphoid cancers, and a 
subset of 52 control samples. Solid tumors, cell lines, and the remaining 498 control samples were screened for CALR 
mutations from existing whole-exome or whole-genome sequencing data. MALT denotes mucosa-associated lymphoid 
tissue, RARS refractory anemia with ringed sideroblasts, and RCMD refractory cytopenias with multilineage dysplasia.
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K368fs*51 QDEEQRL-----------RRRQRTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA      417
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K385fs*47 QDEEQRLKEEEEDKKRKEEEEAEDRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 430
K385fs*47 QDEEQRLKEEEEDKKRKEEEEAEDRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 430
Complex
R376fs*55 QDEEQRLKEEEEDKK-KRRRRQRTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 429
K385fs*47 QDEEQRLKEEEEDKKRKEEEEAED-RMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 430
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tion was an early event in most patients. How-
ever, such predictions should be interpreted cau-
tiously because of the low sequencing coverage 
of CALR and because the approaches we used 
may not distinguish distinct tumor subclones 
with similar tumor burdens. Therefore, the or-
der of mutation acquisition was determined in 
five patients with mutated CALR by genotyping 
300 individual hematopoietic colonies for somatic 
mutations identified on exome sequencing. In all 
five patients, CALR mutations arose in the earli-
est phylogenetic node, consistent with mutation 
of CALR being an initiating event in these pa-
tients (Fig. 4F).
Discussion
Understanding the molecular basis for essential 
thrombocythemia and myelofibrosis in patients 
without JAK2 mutations has been a major goal in 
the field of myeloproliferative neoplasms. In this 
study, we found that CALR, a previously unrecog-
nized oncogene, is mutated in 70 to 84% of pa-
tients with essential thrombocythemia or myelo-
fibrosis without JAK2 or MPL mutations. We also 
describe a comprehensive characterization of the 
mutational landscape of BCR-ABL–negative myelo-
proliferative neoplasms. We found that the me-
dian number of somatic mutations per patient 
was similar to that seen in other hematologic 
cancers (e.g., acute myeloid leukemia, acute lym-
phoblastic leukemia, and chronic lymphocytic 
leukemia, in which the median number of so-
matic mutations ranges from 8 to 13) but was 
substantially lower than the median number 
seen in most common epithelial cancers (range, 
30 to 70).36,37 There was a long tail of cancer 
genes that have been implicated previously in 
myeloid cancers, with each gene mutated in a 
small fraction of patients with myeloprolifera-
tive neoplasms, as well as somatic mutations in 
CHEK2, which have not been described previously 
in myeloproliferative neoplasms.
CALR is present in the endoplasmic reticulum, 
where it forms a key component of the quality-
control machinery that ensures proper glycopro-
tein folding and also contributes to calcium 
homeostasis.29,30 In addition, CALR functions 
outside the endoplasmic reticulum, in the cyto-
plasm, at the cell surface, and in the extracellu-
lar matrix, to influence a variety of processes, 
including proliferation, apoptosis, phagocytosis, 
and immune responses.31-33,37,39 Although calre-
ticulin has been implicated in promoting the 
survival of malignant cells and in their ability to 
generate immune responses,32-34 to our knowl-
edge, somatic mutations affecting endoplasmic 
reticulum chaperones have not been reported in 
any cancer. We describe 19 different CALR muta-
tions (all deletions, insertions, or both) that gen-
erate a +1 base-pair frameshift predicted to re-
place the canonical C-terminal by a novel protein 
sequence. The normal CALR C-terminal domain 
is highly acidic and contains multiple calcium-
binding sites together with a retrieval sequence 
(KDEL) that is typical of endoplasmic reticulum 
resident proteins. In contrast, the new predicted 
C-terminal domain of mutant CALR is basic, 
lacks multiple calcium-binding sites, and has no 
KDEL sequence. Mutant CALR did not have an 
altered Golgi or cell-surface accumulation of 
CALR, which was consistent with previously re-
ported KDEL-independent retention mechanisms 
in the endoplasmic reticulum.40 However, our 
data indicate that mutant CALR probably has 
acquired novel functionality within or outside 
the endoplasmic reticulum.
Current diagnostic guidelines for patients 
with myeloproliferative neoplasms without JAK2 
or MPL mutations rely on the ruling out of reactive 
Figure 3 (facing page). Altered Protein Reading Frame 
with Novel C-Terminal Associated with CALR Mutations.
Panel A shows the functional domains of CALR pro-
tein, with (from left to right) signal sequence, N do-
main (N-terminal), P domain (proline-rich), C domain 
(C-terminal), and KDEL (endoplasmic reticulum reten-
tion signal). The conservation of the affected portion 
of the C domain across species is depicted by shading, 
with black indicating conserved regions and gray indi-
cating partially conserved regions. The range of frame-
shift insertion and deletion mutations in CALR exon 9 
are shown, all of which result in a common +1 base-
pair–altered reading frame and predict a novel C-termi-
nal peptide sequence lacking the KDEL motif. Panel B 
shows the mutational spectra of CALR in samples of 
myeloproliferative neoplasms (MPN) and of common 
loss-of-function genes such as ASXL1 and TET2 in my-
eloproliferative neoplasms and acute myeloid leukemia 
(AML). The numbers of each type of mutation are indi-
cated for each gene. Data regarding myeloproliferative 
neoplasms are from the exome subgroup in this study, 
and AML data are from the Cancer Genome Atlas.36
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causes of thrombocytosis combined with exami-
nation of bone marrow–biopsy specimens.11,13,14 
In our exome subgroup, mutations in CALR, 
JAK2, or MPL were present in 146 of 151 patients 
with myeloproliferative neoplasms (97%). CALR 
mutations were present in 26 of 31 patients 
without JAK2 or MPL mutations in the exome 
subgroup (84%) and in 110 of 158 patients in the 
follow-up subgroup (70%), with the lower preva-
lence in the latter group possibly reflecting 
limitations of Sanger sequencing of whole-blood 
samples. Detection of CALR mutations in periph-
eral blood could potentially be used as a diag-
nostic tool in the same way that tests for JAK2 
mutations have simplified and improved the ac-
curacy of diagnosis of patients with myeloprolif-
erative neoplasms worldwide.11-14 Further re-
search is needed to explore these potential uses.
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Figure 4 (facing page). Localization of Calreticulin and Clonal Heterogeneity in Patients with CALR Mutations.
Panel A shows immunoblotting of transiently transfected human embryonic kidney (HEK) 293T cells analyzed for FLAG 
(a polypeptide protein tag), CALR (detecting endogenous as well as transfected calreticulin), and beta-actin. The CALR 
deletion is the L367fs*46 variant, and the CALR insertion is the K385fs*47 variant. The CALR expression construct is 
shown above the immunoblots. CMV-Pr denotes CMV promoter. Panel B shows confocal photomicrographs of COS-7 
cells transiently expressing FLAG-tagged CALR variants and a Golgi reporter (galactosyltransferase fused to yellow fluo-
rescent protein [GalT-YFP]). Red indicates FLAG; green, Golgi; and blue, nucleus (4′,6-diamidino-2-phenylidole dihydro-
chloride [DAPI]). The images show that nonmutant and mutant CALR have an endoplasmic reticulum localization pat-
tern with no increased accumulation in the Golgi. Panel C shows confocal photomicrographs of COS-7 cells transiently 
coexpressing nonmutant (NM) CALR tagged with green fluorescent protein (GFP) and FLAG-tagged CALR variants. 
Merge images show that FLAG-tagged CALR variants colocalize with nonmutant CALR to the endoplasmic reticulum. 
Panel D shows confocal photomicrographs of myeloid cells from CALR mutated and nonmutated granulocyte–macro-
phage  colony-forming unit colonies derived from a patient with essential thrombocythemia with the CALR K385fs*47 
mutation; the cells have been stained for protein disulfide isomerase (PDI, a resident protein of the endoplasmic retic-
ulum) and endogenous CALR. Panel E shows flow cytometric analysis indicating the degree of CALR cell-surface ex-
pression in granulocytes (G) and lymphocytes (L) from a healthy control and from a patient with mutated CALR. The 
graph shows the percentage of viable cells expressing cell-surface CALR in peripheral blood from healthy controls (tri-
angles) and patients with mutated CALR (circles). FSC denotes forward scatter. Panel F shows clonal structures in five 
patients (indicated by their patient-identification numbers) with myeloproliferative neoplasms with mutated CALR, as 
determined on genotyping of hematopoietic (erythroid) colonies. Each circle represents a clone, with nonmutant 
clones shown in white and mutant clones in brown. The earliest detectable clone is represented at the top of each dia-
gram, with subsequent subclones shown below. Somatic mutations that were acquired in each subclone are indicated 
beside the respective nodes and represent those that were acquired in addition to mutations present in earlier sub-
clones. Numbers of colonies that were identified for each node are shown inside the circles. ET denotes essential 
thrombo cythemia, and PET-MF post-ET myelofibrosis.
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